NCT05646563 - Study of NM8074 in Adult PNH Patients with Inadequate Response to Soliris | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

May 31, 2027

Study Completion Date

January 31, 2028

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

NM8074

NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.

DRUG

Soliris

Complement C5 blocker administered intravenously